	US 12,403,165 B2
	Oncolytic immunotherapy by tumor micro-environment remodeling
Stephen Howard Thorne, Pittsburgh, PA (US); Mingrui Zhang, Pittsburgh, PA (US); and Daniel J. Byrd, Pittsburgh, PA (US)
Assigned to KaliVir Immunotherapeutcs, Inc., Pittsburgh, PA (US)
Filed by KaliVir Immunotherapeutics, Inc., Pittsburgh, PA (US)
Filed on Feb. 3, 2023, as Appl. No. 18/105,374.
Application 18/105,374 is a continuation of application No. PCT/US2021/059887, filed on Nov. 18, 2021.
Claims priority of provisional application 63/116,004, filed on Nov. 19, 2020.
Prior Publication US 2023/0256041 A1, Aug. 17, 2023
Int. Cl. A61K 35/768 (2015.01); A61P 35/00 (2006.01); C07K 14/55 (2006.01); C07K 14/575 (2006.01); C07K 14/715 (2006.01); C12N 15/86 (2006.01)

CPC A61K 35/768 (2013.01) [A61P 35/00 (2018.01); C07K 14/55 (2013.01); C07K 14/5759 (2013.01); C07K 14/7158 (2013.01); C12N 15/86 (2013.01); C12N 2710/24132 (2013.01); C12N 2710/24143 (2013.01); C12N 2710/24171 (2013.01)]

27 Claims

1. A modified oncolytic virus comprising:

an exogenous nucleic acid encoding a fusion protein comprising a metabolic modulating protein, wherein the exogenous nucleic acid encoding for the fusion protein comprises:

a region encoding for an IL-2 polypeptide, and

a region encoding for a leptin polypeptide;

an exogenous nucleic acid encoding a chemokine receptor, wherein the chemokine receptor is CCR2; and

a genetic modification in a viral genome of the modified oncolytic virus, wherein the modified oncolytic virus provides for enhanced tumor volume reduction upon systemic delivery to a subject compared to systemic administration of an otherwise identical oncolytic virus not comprising the exogenous nucleic acid encoding the fusion protein.